After a crushing PhIII failure, Cytokinetics says its next-gen muscle drug is lining up well in PhII — but big challenges loom
For the past 6 months, Cytokinetics $CYTK CEO Robert Blum has been holding things together in the wake of a devastating late-stage disaster that swept away its lead muscle drug. He takes pride in the fact that he was able to soldier on without gutting the staff. And now the biotech and its partners at Astellas are stepping forward with their follow-up drug — looking to persuade investors that they can learn from the grievous setback and make a comeback in the field of strengthening patients afflicted by a range of ailments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.